Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma
- 1 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 29 (1), 467-475
- https://doi.org/10.1007/s00520-020-05493-y
Abstract
Purpose Relapsed or refractory multiple myeloma (RRMM) is labeled "symptomatic" based on laboratory values, but not relevant to quantitative measure of patient's perspectives. This study aimed to describe symptom burden, health status, and quality of life in RRMM patients. Methods The cross-sectional study included 184 MM patients (141 RRMM cases and 43 MM patients on follow-up without diagnosis/treatment of RRMM disease as controls), while 64 RRMM patients also provided longitudinal patient-reported outcomes (PROs) data. Symptomatic status was based on clinical measures of disease activity. PROs included the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM), single-item quality of life (SIQOL), and EuroQol-5D (EQ-5D). Wilcoxon rank test and effect size were used for comparisons. Regression models were used to describe symptom trajectory and to identify predictors of high symptom burden during 3 months of RRMM therapy. Results Most patients were clinically identified as symptomatic (93%). RRMM patients tended to report more severe symptoms, with significantly lower QOL scores and more severe fatigue, poor appetite, and lower enjoyment of life compared with controls (all p < 0.05). In RRMM patients, lower hemoglobin and higher B-2 microglobulin levels significantly correlated with higher burdens of fatigue, pain, and muscle weakness and also with lower QOL and EQ-5D scores (all p < 0.05). During RRMM therapy, being female, with any comorbidity, >= 65 years old, and >= 5 years MM history, contributed to high symptoms burden and poor QOL status (each p < 0.05). Conclusions MDASI-MM modules were sensitive to detect the RRMM-related symptoms burden, which correlated with objective clinical measures. RRMM patients reported a more compromised QOL.Funding Information
- National Institutes of Health (P30CA016672)
- Bristol-Myers Squibb (Bristol-Myers Squibb)
This publication has 32 references indexed in Scilit:
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsHaematologica, 2013
- Validation of the M. D. Anderson Symptom Inventory multiple myeloma moduleJournal of Hematology & Oncology, 2013
- Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyEuropean Journal of Haematology, 2012
- Health‐related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendationsEuropean Journal of Haematology, 2009
- Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyBritish Journal of Haematology, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literatureCancer, 2007
- Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase InhibitorsClinical Cancer Research, 2004
- Health‐related quality of life assessed before and during chemotherapy predicts for survival in multiple myelomaBritish Journal of Haematology, 1997
- Assessment of quality of life in clinical trialsStatistics in Medicine, 1991